This study will investigate the safety and efficacy of the investigational use of the
HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients
with obesity (Class 1, BMI 30-35 kg/m2) and type 2 diabetes who have not achieved targeted
levels... expand

This study will investigate the safety and efficacy of the investigational use of the
HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients
with obesity (Class 1, BMI 30-35 kg/m2) and type 2 diabetes who have not achieved targeted
levels of blood glucose control using oral diabetes medications. The previously FDA-cleared
(for liposuction and fat transfer) HydraSolve T2D™ System will be used to perform a novel,
minimally invasive laparoscopic and mini-laparotomy procedure to selectively remove excess
intra-abdominal fat from the mesentery (Mesenteric Visceral Lipectomy (MVL)), while not
affecting surrounding tissues. The study will include several weeks of screening for
eligibility before the intervention, and 12-months of follow-up post-surgery.

The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
expand

The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

This study evaluates the use of carfilzomib in combination with cyclophosphamide and
etoposide for children with relapsed/refractory solid tumors or leukemia. The medications
cyclophosphamide and etoposide are standard drugs often used together for the treatment of
cancer in... expand

This study evaluates the use of carfilzomib in combination with cyclophosphamide and
etoposide for children with relapsed/refractory solid tumors or leukemia. The medications
cyclophosphamide and etoposide are standard drugs often used together for the treatment of
cancer in children with solid tumors or leukemia.
Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults
with multiple myeloma (a type of cancer). However, this drug is not approved for the disease
being treated in this study. Since carfilzomib has not yet been used in this setting to treat
this condition, the investigators must first find the best dose to give. The investigators
are looking for the highest dose of carfilzomib that can be given safely. Therefore, not all
children taking part in this study will receive the same dose of the study drug in the first
part of the trial.

VA Office of Research and DevelopmentPTSDPosttraumatic Stress Disorder

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as
compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an
active duty military and Veteran population.
expand

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as
compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an
active duty military and Veteran population.

AO Clinical Investigation and DocumentationBilateral Condylar Fracture of the Mandible

Prospective data will be collected in approximately 250 patients sustaining BCFx with or
without any additional fracture(s) of the symphysis. Patients will be followed according to
the standard (routine) at approximately 6 weeks and 3 months after the treatment. Data
collection... expand

Prospective data will be collected in approximately 250 patients sustaining BCFx with or
without any additional fracture(s) of the symphysis. Patients will be followed according to
the standard (routine) at approximately 6 weeks and 3 months after the treatment. Data
collection will include fracture details (i.e. classification, mechanism of injury),
treatment details, functional and patient-reported outcomes, and anticipated or
procedure-related adverse events (i.e. complications).

This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in
treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600
mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help
repair... expand

This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in
treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600
mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help
repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so
tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high
energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as
temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib,
radiation therapy, and temozolomide may work better in treating patients with newly diagnosed
malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and
temozolomide alone.

The University of Texas Health Science Center at San AntonioPosttraumatic Stress Disorder

The open-label clinical study explores potential modifiable predictors of treatment outcomes
in a sample of 55 military service members and veterans with clinically significant PTSD
symptoms who receive Intensive Outpatient Prolonged Exposure (IOP-PE).
expand

The open-label clinical study explores potential modifiable predictors of treatment outcomes
in a sample of 55 military service members and veterans with clinically significant PTSD
symptoms who receive Intensive Outpatient Prolonged Exposure (IOP-PE).

This randomized phase III trial studies how well combination chemotherapy (vincristine
sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan
hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in
treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as
muscle), and has an intermediate chance of coming back after treatment (intermediate risk).
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy
or combination chemotherapy plus temsirolimus is more effective in treating patients with
intermediate-risk rhabdomyosarcoma.

This is a multicenter, open-label, safety study. Eligible subjects will be adults with
advanced malignancies. The study includes a pretreatment and treatment phase. The
pretreatment phase consists of screening and baseline periods. The treatment phase consists
of 4-week treatment... expand

This is a multicenter, open-label, safety study. Eligible subjects will be adults with
advanced malignancies. The study includes a pretreatment and treatment phase. The
pretreatment phase consists of screening and baseline periods. The treatment phase consists
of 4-week treatment periods and a follow-up period.

The University of Texas Health Science Center at San AntonioProstate Cancer

Research repository designed to establish prostate cancer upgrading reference set and
development of a risk prediction tool. Repository will include clinical information and
biologics on a cohort of 240 men, to predict presence of high grade cancer at time of
prostatectomy (removal... expand

Research repository designed to establish prostate cancer upgrading reference set and
development of a risk prediction tool. Repository will include clinical information and
biologics on a cohort of 240 men, to predict presence of high grade cancer at time of
prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time
of biopsy.

This study is to determine if a new bone adhesive is useful in stabilizing dental tooth
implants. Data collected from the study will examine the strength, performance, and the
safety of the material.
expand

This study is to determine if a new bone adhesive is useful in stabilizing dental tooth
implants. Data collected from the study will examine the strength, performance, and the
safety of the material.

This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard
of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with
breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6... expand

This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard
of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with
breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6
inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) .

The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize
information collected in the medical record to learn more about a disease called amyotrophic
lateral sclerosis (ALS) and related disorders.
expand

The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize
information collected in the medical record to learn more about a disease called amyotrophic
lateral sclerosis (ALS) and related disorders.

The University of Texas Health Science Center at San AntonioDiabetes Mellitus, Type 2

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous
glucose production) and plasma glucose concentration in diabetic subjects. Researchers will
examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and
fall in... expand

In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous
glucose production) and plasma glucose concentration in diabetic subjects. Researchers will
examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and
fall in plasma glucose concentration.

The University of Texas Health Science Center at San AntonioHepatocellular Cancer

The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when
compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ
would lead to disease stability in patients with advanced hepatocellular cancer (HCC).
expand

The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when
compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ
would lead to disease stability in patients with advanced hepatocellular cancer (HCC).

The purpose of this first-in-human study of MBG453 is to characterize the safety,
tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453
administered i.v. as a single agent or in combination with PDR001 or decitabine in adult
patients with advanced... expand

The purpose of this first-in-human study of MBG453 is to characterize the safety,
tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453
administered i.v. as a single agent or in combination with PDR001 or decitabine in adult
patients with advanced solid tumors

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to
identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone
effects in ALS. Epigenetic and protein biomarkers will also be investigated.
expand

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to
identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone
effects in ALS. Epigenetic and protein biomarkers will also be investigated.

This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab
vedotin) when given with combination chemotherapy in treating patients with newly diagnosed
stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody,
brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in
a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as
doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. The addition of nivolumab or brentuximab vedotin to combination
chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.

The University of Texas Health Science Center at San AntonioPost Traumatic Stress Disorder

A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for
veterans considering prolonged exposure (PE) therapy, following the model established by Foa
et al, we need to establish safety, and feasibility of quetiapine compared to treatment as... expand

A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for
veterans considering prolonged exposure (PE) therapy, following the model established by Foa
et al, we need to establish safety, and feasibility of quetiapine compared to treatment as
usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.

The University of Texas Health Science Center at San AntonioBladder Cancer

This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention"
refers to surveillance based on the European Association of Urology (EAU) guidelines and the
"control" refers to surveillance based on the American Urological Association (AUA)
guidelines.... expand

This is a two-arm, randomized-controlled pilot study with 2 year duration. The "intervention"
refers to surveillance based on the European Association of Urology (EAU) guidelines and the
"control" refers to surveillance based on the American Urological Association (AUA)
guidelines.

This phase II trial studies how well axitinib and nivolumab work in treating patients with
TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or
has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor
cells... expand

This phase II trial studies how well axitinib and nivolumab work in treating patients with
TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or
has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab
may work better in treating patients with TFE/translocation renal cell carcinoma compared to
standard treatment, including surgery, chemotherapy, or immunotherapy.

The University of Texas Health Science Center at San AntonioInsulin Sensitivity

Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action,
particularly on adipose tissue.
Research Design/Plan: Normal glucose tolerant subjects will be studied. Study subjects will
receive a continuous glucagon infusion for 12 hours. Following glucagon... expand

Purpose/Objectives: To investigate the effect of hyperglucagonemia on insulin action,
particularly on adipose tissue.
Research Design/Plan: Normal glucose tolerant subjects will be studied. Study subjects will
receive a continuous glucagon infusion for 12 hours. Following glucagon infusion, subjects
will receive prime-continuous tracer infusions for additional 4 hours to measure adipocyte
metabolism. Within 6-8 weeks, subjects will return for a repeat study with normal saline as a
control group.
Methods: All subjects will have an oral glucose tolerance test prior to participation to
confirm they are normal glucose tolerant. Subjects will be admitted to the CRC at 4 PM and
will receive a continuous glucagon for 12 hours. At 6 AM on the following morning, subjects
will receive prime-continuous tracer infusions of the following for 4 hours (14C-glycerol,
3-3H glucose, and D2O). At 10 AM continuous indirect calorimetry will be performed to
determine rates of energy expenditure and glucose/lipid oxidation for 40 minutes. At 6 AM a
surgical biopsy of abdominal adipose tissue will be performed for measurement of adipocyte
metabolism. At 8 AM, the study team will infuse insulin/glucose to test for insulin
sensitivity.
Clinical Relevance: The results of this study will help the study team to further understand
the pathophysiology of metabolic disturbances that is induced by hyperglucagonemia in type 2
diabetes patients.

The University of Texas Health Science Center at San AntonioProstatic Neoplasm

The goal of this study is to demonstrate the impact of a home based exercise program versus
wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer
under active surveillance.
expand

The goal of this study is to demonstrate the impact of a home based exercise program versus
wait-list control to modulate circulating prognostic biomarkers in men with prostate cancer
under active surveillance.

This partially randomized clinical trial studies surgery or non-surgical management in
treating patients with intra-abdominal cancer and bowel obstruction. Bowel obstruction is a
common problem for advanced cancer patients and can negatively affect quality of life. It is
not... expand

This partially randomized clinical trial studies surgery or non-surgical management in
treating patients with intra-abdominal cancer and bowel obstruction. Bowel obstruction is a
common problem for advanced cancer patients and can negatively affect quality of life. It is
not yet known whether surgery or non-surgical management is the best treatment option for
bowel obstruction and can lead to better quality of life.

The primary objective of this study is to compare Assay results to diagnoses determined by
currently accepted standards for lung cancer detection. This will be accomplished by analysis
of sputum samples from three cohorts including healthy Participants, high risk Participants,... expand

The primary objective of this study is to compare Assay results to diagnoses determined by
currently accepted standards for lung cancer detection. This will be accomplished by analysis
of sputum samples from three cohorts including healthy Participants, high risk Participants,
and cancer patient Participants using the Assay as developed in accordance with findings of
bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary
to finalize Assay design for clinical trials and commercialization.
The secondary objective of this study is to determine optimum methods for collection of
sputum samples. Three sputum collection methods used by high risk Participants will be
compared. Individuals at high risk for lung cancer will be assigned to one of three sputum
collection cohorts including (1) acapella® airway assist device under medical supervision to
obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample
over a three-day period, and (3) individuals who under medical supervision will collect a
single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline.
Samples will be compared to determine the optimal collection method for sample analysis by
CyPath® Lung.